Niaspan Reverse Payment Antitrust Litigation
Court: United States District Court, Eastern District of Pennsylvania
Case No.: 13-md-2460
Leadership Position: Interim Co-Lead Counsel
Wexler Boley & Elgersma LLP is Interim Co-Lead Counsel for the end purchaser plaintiffs in an antitrust class action against AbbVie Inc. and Teva Pharmaceuticals USA, Inc. (and related companies) involving the cholesterol drug Niaspan. The plaintiffs allege that the defendants conspired to keep a generic version of Niaspan off the market for more than eight years. The plaintiffs have also alleged that the defendants’ conduct caused consumers and drug benefit plans to pay more for Niaspan and its generic equivalents than they otherwise would have, in violation of state antitrust and consumer protection laws.
To view a copy of the consolidated class action complaint, click here.